{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:05Z","timestamp":1793933165809,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have shown good efficacy in migraine prophylaxis. However, a subset of patients does not respond to the first mAb treatment and switches among the available mAbs. The goal of this study is to characterize the switching pattern of migraine patients treated with anti-CGRP(-receptor, -R) mAbs, and to describe the headache burden of those who did not switch, switched once, and switched twice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study used real world data from the NeuroTransData Cohort, a registry of migraine patients treated at outpatient neurology clinics across Germany. Patients who had received at least one anti-CGRP(-R) mAb were included. Headache diaries were collected at baseline and during treatment, along with quality of life measures every three months. Results were summarized for the subgroups of patients who did not switch and those with one and two switches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 655 eligible patients, 479 did not switch, 135 switched once, 35 twice, and 6 three or more times. The \u2265\u200950% response rates for monthly migraine days were 64.7%, 50.7%, and 25.0% for the no switch, one switch, and two switches groups in their last treatment cycles, respectively. Quality of life measures improved for the no switch and one switch groups, but not for the two switches group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients who switched among anti-CGRP(-R) mAbs during the course of their treatment still benefited overall but to a lesser extent than those who did not switch. Treatment response in patients who switched twice was markedly lower compared to the no switch and one switch subgroup.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01790-7","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T23:03:19Z","timestamp":1717369399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies \u2013 insights from the German NeuroTransData registry"],"prefix":"10.1186","volume":"25","author":[{"given":"Ja Bin","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Israel-Willner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schanbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"K\u00f6chling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NTD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"1790_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"1790_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K et al (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"1790_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24:56","journal-title":"J Headache Pain"},{"key":"1790_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","volume":"26","author":"AM Murray","year":"2022","unstructured":"Murray AM, Stern JI, Robertson CE et al (2022) Real-world patient experience of CGRP-Targeting therapy for migraine: a Narrative Review. Curr Pain Headache Rep 26:783\u2013794","journal-title":"Curr Pain Headache Rep"},{"key":"1790_CR5","doi-asserted-by":"publisher","first-page":"033310242311593","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D et al (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43:033310242311593","journal-title":"Cephalalgia"},{"key":"1790_CR6","doi-asserted-by":"publisher","first-page":"1154420","DOI":"10.3389\/fneur.2023.1154420","volume":"14","author":"LH Overeem","year":"2023","unstructured":"Overeem LH, Lange KS, Fitzek MP et al (2023) Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol 14:1154420","journal-title":"Front Neurol"},{"key":"1790_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291\u2013301","journal-title":"Cephalalgia"},{"key":"1790_CR8","doi-asserted-by":"publisher","first-page":"033310242311605","DOI":"10.1177\/03331024231160519","volume":"43","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Burgalassi A, Vigani G et al (2023) Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia 43:033310242311605","journal-title":"Cephalalgia"},{"key":"1790_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12883-023-03203-9","volume":"23","author":"K Kaltseis","year":"2023","unstructured":"Kaltseis K, Filippi V, Frank F et al (2023) Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an Austrian case series. BMC Neurol 23:174","journal-title":"BMC Neurol"},{"key":"1790_CR10","doi-asserted-by":"crossref","unstructured":"International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018); 38: 1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"1790_CR11","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"S De Vries Lentsch","year":"2021","unstructured":"De Vries Lentsch S, Verhagen IE, Van Den Hoek TC et al (2021) Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real\u2010life study. Euro J Neurol 28:4194\u20134203","journal-title":"Euro J Neurol"},{"key":"1790_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M et al (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61","journal-title":"J Headache Pain"},{"key":"1790_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"for the GARLIT Study Group, Vernieri F, Altamura C et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35","journal-title":"J Headache Pain"},{"key":"1790_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1790_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q et al (2018) Evaluation of Galcanezumab for the Prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 75:1080","journal-title":"JAMA Neurol"},{"key":"1790_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21:597\u2013607","journal-title":"Lancet Neurol"},{"key":"1790_CR17","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38:1442\u20131454","journal-title":"Cephalalgia"},{"key":"1790_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Fitzek M, Overeem LH et al (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain 24:16","journal-title":"J Headache Pain"},{"key":"1790_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-023-01593-2","volume":"24","author":"A Straube","year":"2023","unstructured":"Straube A, Broessner G, Gaul C et al (2023) Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain 24:59","journal-title":"J Headache Pain"},{"key":"1790_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-023-01569-2","volume":"24","author":"A Kuburas","year":"2023","unstructured":"Kuburas A, Russo AF (2023) Shared and independent roles of CGRP and PACAP in migraine pathophysiology. J Headache Pain 24:34","journal-title":"J Headache Pain"},{"key":"1790_CR21","doi-asserted-by":"publisher","first-page":"105946","DOI":"10.1016\/j.nbd.2022.105946","volume":"176","author":"S Guo","year":"2023","unstructured":"Guo S, Jansen-Olesen I, Olesen J et al (2023) Role of PACAP in migraine: an alternative to CGRP? Neurobiol Dis 176:105946","journal-title":"Neurobiol Dis"},{"key":"1790_CR22","doi-asserted-by":"publisher","first-page":"033310242211478","DOI":"10.1177\/03331024221147881","volume":"43","author":"S Ashina","year":"2023","unstructured":"Ashina S, Melo-Carrillo A, Szabo E et al (2023) Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: a prospective quantitative sensory testing study (NCT04271202). Cephalalgia 43:033310242211478","journal-title":"Cephalalgia"},{"key":"1790_CR23","doi-asserted-by":"publisher","unstructured":"Hong JB, Lange KS, Overeem LH et al A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response. Pharmaceuticals; 16. Epub ahead of print 2023. https:\/\/doi.org\/10.3390\/ph16070934","DOI":"10.3390\/ph16070934"},{"key":"1790_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10194-020-01111-8","volume":"21","author":"M Torres-Ferr\u00fas","year":"2020","unstructured":"On behalf of School of Advanced Studies of European Headache Federation (EHF-SAS), Torres-Ferr\u00fas M, Ursitti F et al (2020) From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 21:42","journal-title":"J Headache Pain"},{"key":"1790_CR25","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez-Rodr\u00edguez C, Gago-Veiga AB, Garc\u00eda-Azor\u00edn D et al Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data. Curr Pain Headache Rep. Epub ahead of print 24 October 2023. https:\/\/doi.org\/10.1007\/s11916-023-01183-6","DOI":"10.1007\/s11916-023-01183-6"},{"key":"1790_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s13311-023-01394-0","volume":"20","author":"G Lambru","year":"2023","unstructured":"Lambru G, Caponnetto V, Hill B et al (2023) Long-term effect of switching from an Anti-CGRP receptor to an Anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics 20:1284\u20131293","journal-title":"Neurotherapeutics"},{"key":"1790_CR27","doi-asserted-by":"crossref","unstructured":"Talbot J, Stuckey R, Wood N et al (2024) Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab. Eur J Hosp Pharm; ejhpharm-2023-003779.","DOI":"10.1136\/ejhpharm-2023-003779"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01790-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01790-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01790-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T23:03:24Z","timestamp":1717369404000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01790-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01790-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}